COHRCoherent Corp.

On December 8, 2025, Jim Anderson, the Company’s Chief Executive Officer and a director on the Company’s board, entered into a 10b5-1 trading arrangement (the “10b5-1 Plan”) for the potential sale of a portion of the net shares of Company common stock resulting from the performance share award vesting on June 30, 2027. The 10b5-1 Plan, scheduled to commence on July 1, 2027, is intended to satisfy the affirmative defense of Rule 10b5-1(c) and will terminate on the earlier of (1) the date all the shares under the 10b5-1 Plan are sold or (2) December 1, 2027.

On December 3, 2025 Stephen Skaggs, a director on the Company’s board, entered into a 10b5-1 trading arrangement (the “10b5-1 Plan”) for the sale of 5,795 shares of the Company’s common stock. The 10b5-1 Plan, scheduled to commence on March 9, 2026, is intended to satisfy the affirmative defense of Rule 10b5-1(c) and will terminate on December 31, 2026.

On November 21, 2025, Dr. Julie Eng, the Company’s Chief Technology Officer, entered into a 10b5-1 trading arrangement (the “10b5-1 Plan”) for the sale of 1,454 shares of the Company’s common stock and the potential sale of up to one hundred percent of the shares of Company common stock resulting from various performance share and restricted share award vesting in 2026 and 2027. The 10b5-1 Plan, scheduled to commence on February 20, 2026, is intended to satisfy the affirmative defense of Rule 10b5-1(c) and will terminate on March 5, 2027.

On November 13, 2025, Sherri Luther, the Company’s Chief Financial Officer, entered into a 10b5-1 trading arrangement (the “10b5-1 Plan”) for the sale of 12,000 shares of the Company’s common stock. The 10b5-1 Plan, scheduled to commence on February 12, 2026, is intended to satisfy the affirmative defense of Rule 10b5-1(c) and will terminate on August 19, 2026.

On May 13, 2025, Julie Eng, the Company’s CTO, terminated a written plan intended to satisfy the affirmative defense of Rule 10b5-1(c) which was adopted on December 1, 2024, with a duration through July 31, 2026, and with respect to the sale of up to 9,278 Company shares. On May 15, 2025, she adopted a written plan intended to satisfy the affirmative defense of Rule 10b5-1(c) with a duration through March 3, 2026 with respect to the sale of 100% of Company shares (net shares surrendered to the Company or sold to cover taxes) acquired in connection with the Company’s Restricted Stock Plan for employees/executives and vesting on August 28, 2025 and February 28, 2026.

On December 9, 2024, Christopher Koeppen, the Company’s Chief Innovation Officer and SVP, Aerospace & Defense, adopted a written plan intended to satisfy the affirmative defense of Rule 10b5-1(c) with a duration through December 31, 2025 with respect to the sale of up to 31,741 Company shares.

On December 6, 2024, Giovanni Barbarossa, the Company’s Chief Strategy Officer and President, Materials Segment, adopted a written plan intended to satisfy the affirmative defense of Rule 10b5-1(c) with a duration through December 31, 2026 with respect to the sale of up to 120,186 Company shares.

On December 1, 2024, Julie Eng, the Company’s Chief Technology Officer, adopted a written plan intended to satisfy the affirmative defense of Rule 10b5-1(c) with a duration through July 31, 2026 with respect to the sale of up to 9,278 Company shares.